Paper914
Overview: maintenance therapy in psychiatry: I. Schizophrenia.
Davis JM. Am J Psychiatry, 1975. Cited by 394 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Overview: maintenance therapy in psychiatry: I. Schizophrenia. Papers, record 914. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/914
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antipsychotic Agents | Major topic |
| Schizophrenia | Major topic |
| Clinical Trials as Topic | |
| Drug Evaluation | |
| Female | |
| Fluphenazine | |
| Humans | |
| Male | |
| Recurrence | |
| Research Design | |
| Time Factors |
Source PubMed
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 394 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,157,201 | Psychiatric hospitalization and rehospitalization among children and adolescents: evidence from 10-years electronic records in Beijing, China. | BMC Psychiatry | 2026 | https://conductscience.org/library/papers/42157201 | PubMed |
| 41,288,687 | Clinical outcomes in first-episode schizophrenia: identifying predictors of relapse. | Soc Psychiatry Psychiatr Epidemiol | 2026 | https://conductscience.org/library/papers/41288687 | PubMed |
| 39,144,771 | Antipsychotic Maintenance Treatment for Patients With Schizophrenia: The Need for Placebo-Controlled Trials and The Risk of Paradigm Shifts. | Schizophr Bull Open | 2022 | https://conductscience.org/library/papers/39144771 | PubMed |
| 34,768,521 | Risk Factors for Revolving Door in Children and Adolescents with Psychiatric Disorders. | J Clin Med | 2021 | https://conductscience.org/library/papers/34768521 | PubMed |
| 32,840,872 | Maintenance treatment with antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2020 | https://conductscience.org/library/papers/32840872 | PubMed |
| 31,006,114 | Haloperidol discontinuation for people with schizophrenia. | Cochrane Database Syst Rev | 2019 | https://conductscience.org/library/papers/31006114 | PubMed |
| 26,508,952 | Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based Study. | Psychiatry Investig | 2015 | https://conductscience.org/library/papers/26508952 | PubMed |
| 25,290,157 | Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/25290157 | PubMed |
| 25,177,834 | Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/25177834 | PubMed |
| 25,087,165 | Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/25087165 | PubMed |
| 25,007,358 | Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/25007358 | PubMed |
| 25,003,310 | Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia. | Cochrane Database Syst Rev | 2014 | https://conductscience.org/library/papers/25003310 | PubMed |
| 24,596,880 | Rivers of evidence. | Int J Health Policy Manag | 2013 | https://conductscience.org/library/papers/24596880 | PubMed |
| 22,909,285 | Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations. | BMC Psychiatry | 2012 | https://conductscience.org/library/papers/22909285 | PubMed |
| 22,889,923 | Another view of the history of antipsychotic drug discovery and development. | Mol Psychiatry | 2012 | https://conductscience.org/library/papers/22889923 | PubMed |
| 21,286,547 | The stages of schizophrenia and their management. | Can Fam Physician | 1982 | https://conductscience.org/library/papers/21286547 | PubMed |
| 19,176,470 | Psychosocial treatments to promote functional recovery in schizophrenia. | Schizophr Bull | 2009 | https://conductscience.org/library/papers/19176470 | PubMed |
| 18,748,785 | Psychiatry-epitomes of progress: tardive dyskinesia. | West J Med | 1981 | https://conductscience.org/library/papers/18748785 | PubMed |
| 18,245,059 | Cochrane Schizophrenia Group. | Schizophr Bull | 2008 | https://conductscience.org/library/papers/18245059 | PubMed |
| 17,253,586 | Cessation of medication for people with schizophrenia already stable on chlorpromazine. | Cochrane Database Syst Rev | 2007 | https://conductscience.org/library/papers/17253586 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/914
GET https://conductscience.org/api/papers/v1/914/cited_by?page=2